THE HUMAN HIGH-MOBILITY GROUP (HMG)-BOX TRANSCRIPTION FACTOR TCF-1 - NOVEL ISOFORMS DUE TO ALTERNATIVE SPLICING AND USAGE OF A NEW EXON IXA

被引:12
作者
MAYER, K
WOLFF, E
CLEVERS, H
BALLHAUSEN, WG
机构
[1] UNIV ERLANGEN NURNBERG,INST HUMANGENET,D-91054 ERLANGEN,GERMANY
[2] UNIV UTRECHT HOSP,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION | 1995年 / 1263卷 / 02期
关键词
ALTERNATIVE SPLICING; HIGH MOBILITY GROUP BOX; T-CELL; TRANSCRIPTION;
D O I
10.1016/0167-4781(95)00108-S
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The C-terminal peptide sequences of the human lymphocyte-specific high mobility group (HMG)-box transcription factor TCF-1 are determined by alternative splice mechanisms affecting the exons VIII to X. Here we report, in addition to four splice forms described previously (TCF-1A, B, C,D), the identification of three novel transcripts designated TCF-1E, F, G. Cloning and sequencing of the novel cDNAs revealed (i) joining of the exons VIII and IX to an internal exon X splice acceptor site resulting in a new open reading frame (ORF) of 99 amino acids derived from exon X sequences, (ii) the identification of an additional functional splice acceptor site within exon X, and (iii) a new 81-nucleotide insertion between exon VIII and exon X sequences in a novel transcript form. Genomic cloning and sequence analysis of this transcribed segment of 81 basepairs revealed that it was bordered by canonical splice consensus sites and located in a distance of some 400 bp from both the exons IX and X. It was therefore termed exon IXA. Novel ORFs were generated as a consequence of these alternative splice mechanisms resulting in TCF-1 gene products with significantly different C-terminal peptide sequences, which are prone to selective protein-protein interactions or transactivating functions.
引用
收藏
页码:169 / 172
页数:4
相关论文
共 17 条
[1]  
Laudet, Stehelin, Clevers, Nucleic Acids Res., 21, pp. 2493-2501, (1993)
[2]  
Jantzen, Admon, Bell, Tjian, Nature, 344, pp. 830-836, (1990)
[3]  
Parisi, Clayton, Science, 252, pp. 965-969, (1991)
[4]  
Bianchi, Falciola, Ferrari, Lilley, EMBO J., 11, pp. 1055-1063, (1992)
[5]  
Van de Wetering, Oosterwegel, Dooijes, Clevers, EMBO J., 10, pp. 123-132, (1991)
[6]  
Van de Wetering, Clevers, EMBO J., 11, pp. 3039-3044, (1992)
[7]  
Giese, Cox, Grosschedl, Cell, 69, pp. 185-195, (1992)
[8]  
Van de Wetering, Oosterwegel, Holstege, Dooijes, Suijkerbuijk, Geurts van Kessel, Clevers, J. Biol. Chem., 267, pp. 8530-8536, (1992)
[9]  
Clevers, Oosterwegel, Georgopoulos, Immunol. Today, 14, pp. 591-596, (1994)
[10]  
Mayer, Ballhausen, Int. J. Oncol., 3, pp. 369-373, (1993)